Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar.

Date publication

juillet 2022

Journal

Multiple sclerosis and related disorders

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme

Tous les auteurs :
Yamamura T, Weinshenker B, Yeaman MR, De Seze J, Patti F, Lobo P, von Büdingen HC, Kou X, Weber K, Greenberg B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36007339

Résumé

This analysis evaluated long-term safety findings from the SAkuraSky and SAkuraStar studies with satralizumab in patients with neuromyelitis optica spectrum disorder (NMOSD).

Mots clés

All clinical trials, All demyelinating disease (CNS), Autoimmune diseases, Devic's syndrome, Neuromyelitis optica spectrum disorder, Patient safety

Référence

Mult Scler Relat Disord. 2022 07 5;66:104025